Financing R & D for neglected diseases

Abstract

There has recently been a welcome increase in R & D activity to provide much-needed new drugs for neglected diseases of the developing world. This activity has resulted in an early stage pipeline of potential medicines that will require significant new funding if they are to progress to registration - a need that might be addressed by a novel type of funding body.